Association of immune cell recruitment and BPD development

Motaharehsadat Heydarian1, Christian Schulz2,3, Tobias Stoeger1 and Anne Hilgendorff1,4*

Abstract
In the neonatal lung, exposure to both prenatal and early postnatal risk factors converge into the development of injury and ultimately chronic disease, also known as bronchopulmonary dysplasia (BPD). The focus of many studies has been the characteristic inflammatory responses provoked by these exposures. Here, we review the relationship between immaturity and prenatal conditions, as well as postnatal exposure to mechanical ventilation and oxygen toxicity, with the imbalance of pro- and anti-inflammatory regulatory networks. In these conditions, cytokine release, protease activity, and sustained presence of innate immune cells in the lung result in pathologic processes contributing to lung injury. We highlight the recruitment and function of myeloid innate immune cells, in particular, neutrophils and monocyte/macrophages in the BPD lung in human patients and animal models. We also discuss dissimilarities between the infant and adult immune system as a basis for the development of novel therapeutic strategies.

Keywords: Neonate, Lung, Chronic lung disease, Bronchopulmonary dysplasia, Inflammation, Neutrophil, Monocyte, Macrophage

Background
Bronchopulmonary dysplasia (BPD) is the neonatal form of chronic lung disease occurring in the context of prematurity and is characterized by impaired pulmonary development [1]. The consequences of misdirected lung development persist into adulthood, and although the advances in neonatal intensive care decreased the rate of overall mortality after premature birth, the prevalence of chronic complications like BPD remained [2, 3]. Different prenatal and postnatal factors have been introduced as contributors to BPD development, including genetic/epigenetic risk factors, intrauterine hypoxia and growth retardation, infection, mechanical ventilation (MV), and oxygen supplementation [4, 5]. Clinically, BPD is classified into three severity grades according to the need for oxygen supplementation or MV 28 days after birth and near term age, i.e., 36 weeks gestational age (GA) [6]. More than half of the preterm infants that require life-saving postnatal treatment with MV or oxygen supplementation develop subsequent complications such as failure of alveolo- and angiogenesis [7, 8]. Premature babies born before 32 weeks of GA present with a structural and functional immaturity of the lung that includes an immune system not yet equipped to sufficiently respond to environmental insults. The subsequent vulnerability to infections and injury together with the mis-directed role of immune functions in organ development highlights the importance of better understanding—and potentially targeting—immune-related phenomena [9]. Inflammation is a vital element of host defense [10]. Excessive or persistent inflammation, however, is known to interfere with organ development including the lung, and thus, a key contributor to the emergence and pathogenesis of BPD indicating disease progression [11, 12]. Inflammation can be triggered by both prenatal as well as postnatal factors including hyperoxia, MV, and infections [13–16] that act beyond the background, e.g., immaturity and gender [16]. Preterm labor per se is associated with...
intrauterine infections with ureaplasm and mycoplasma infections holding a specific role in BPD development [13]. In consequence, intrauterine and early postnatal infections and the respective inflammation are common in premature infants [17]. The immune system in premature infants is still undeveloped with a lower number of neutrophils and monocytes in the cord blood, resulting in a greater vulnerability to infections and a significant imbalance of pro-and anti-inflammatory mechanisms upon injury [18, 19].

The later development of BPD is then characterized by the accumulation and activation of myeloid leukocytes cells in the lung, which in turn drive pathophysiological processes such as an enhanced permeability of the endothelial and epithelial barrier (“leakage”) [20, 21]. Recently, studies specifically focused on the impact of the accumulation of inflammatory cells, myeloid neutrophils, and monocytes in particular, on misguided alveolar and pulmonary vascular development as the hallmark of BPD [22–24]. However, the bidirectional role of resident and recruited myeloid cells in development and injury has been targeted for the development of treatment strategies. This review provides an overview of the current state of knowledge available on the known and potential role of neutrophils, monocyte/macrophages, and their crosstalk with resident cells in BPD development, side by side with a discussion about the main challenges concerning modeling the disease and future perspectives in the field. The important differences in immune functions when compared to adults are highlighted.

**Innate immunity in the development of neonatal chronic lung disease**

Due to the limited exposure to foreign antigens in utero, the newborn infant relies on innate immunity-dependent defense strategies as the adaptive immune response is still naive [25–27]. Also, the shortened time for the prenatal development of immune functions in preterm infants impacts immune responses immediately after birth [28]. Circulating and resident myeloid immune cells such as neutrophils and monocytes are at the forefront of the innate immune response and act as potential triggers of inflammatory signals including cytokines and chemokines [29], which mediate immune activation as well as the transition from innate to adaptive immunity [30, 31].

Environmental assaults not only encompass bacterial or viral infections but exposure to toxins and mechanical stress as initiated by MV and oxygen supplementation all triggering inflammation involving both innate and adaptive immune responses [32, 33] (see Fig. 1). The airway epithelium is an immunologically active barrier and the main source of pro-inflammatory cytokines [34, 35]. Upon the airway epithelial injury and local release of the classical pro-inflammatory cytokines of the innate immune defense such as interleukin-1, -6, -8 (IL-1, IL-6, IL-8), and tumor necrosis factor-alpha (TNFα), blood neutrophils immediately migrate into the lung tissue, subsequently followed by monocytes which—once recruited—rapidly differentiate into macrophages [36–38]. This monocyte-to-macrophage differentiation is initiated after the emigration from the circulation into the tissue in association with gaining different functional phenotypes dependent on the local tissue environment [39]. Depending on the micro-environmental signals, macrophages develop distinct functions represented in the concept of their differentiation into classical activated, inflammatory (M1) or activated, anti-inflammatory, or fibrotic (M2) states [38]. Furthermore, neonatal and adult alveolar macrophages (AMs) differ from each other and present their unique transcriptome profile under the impact of micro-environmental signals [40].

Studies on BPD research during the last few decades primarily focused on the association between cytokine and chemokine expression patterns and disease onset or progress [41]. Researchers found high expression levels of specific cytokines stemming from classical macrophage activation such as monocyte chemoattractant protein-1 (MCP-1/CCL2), macrophage inflammatory proteins (MIP), the neutrophil chemokine IL-8, and low expression of IL-10 in association with BPD development [12, 42–45] while expression other cytokines, for example, IL-4 and IL-13 did not correlate with BPD [46]. In addition to the myeloid lineage, an increase in type 3 innate lymphoid cells (ILC3) have been reported for their pro-inflammatory role in BPD development, mainly through the secretion of IL-17, which is known as a key factor in the recruitment of neutrophils via stimulation of IL-8 including neutrophils and CXCL1 and CXCL2 chemokines [47, 48]. In contrast, levels of granulocyte colony-stimulating factor (G-CSF), responsible for the stimulation of granulocyte production in the bone marrow (BM), were found to be reduced in preterm when compared to term infants, which indicates the defective function of neutrophils during infection [49]. Thus, a potential therapeutic approach to treat or prevent BPD has been proposed by inhibiting the unsolicited expression of cytokine and chemokine [50, 51], which plays a critical role in preterm infants innate immunity and BPD development.

To delineate specific cellular functions engaged in the innate immune response, we, in the following, specifically outline neutrophil and monocyte/macrophage functions and interactions in light of the sequential order of immune events.
Neonatal neutrophils and their activation in BPD

Neutrophils play an indispensable role in acute lung inflammation in both mature and developing organisms [52–54]. During the initiation phase of inflammation, neutrophils undergo a variety of changes in gene expression and functional properties [55]. Neutrophilic granulocytes originate in the BM and are released into circulation [56], where they act as the first line of cellular immune defense when getting recruited to the site of injury [57]. This first wave of inflammation is followed by the recruitment of monocytes in a later stage. Neutrophils eliminate pathogens through phagocytosis and via releasing proteases, reactive oxygen species (ROS), and bioactive membrane vesicles through a function called degranulation [58]. ROS are highly reactive species formed from \( \text{O}_2 \) such as hydroperoxyl and hydrogen peroxide, and can be transformed into radicals [57, 59]. The sudden postnatal exposure of the immature lung to oxygen and MV is currently seen as the inducer of ROS-dependent local and systemic neutrophilic inflammatory responses [60–62], that in turn can cause the release and activation of neutrophils and increased ROS production [63, 64]. Next to the ROS-induced effects that restrict lung development and contribute to BPD, another destructive role of activated neutrophils in the process of alveolar formation is likely related to the release of exosomes that can increase the proliferation of airway smooth muscle cells, induce remodeling and extracellular matrix (ECM) destruction—all being features of BPD [65–68]. In addition, the release of neutrophil elastase (NE) and metalloproteinases (MMP) like MMP-9 can cleave fibronectin and increase ECM degradation in the alveoli, thereby contributing to scaffold remodelling and BPD progress [69, 70]. Alternatively, these factors can be released by the ECM itself, thereby perpetuating the vicious cycle of damaging the alveolar niche [68]. In line with this, endogenous protease inhibitors, such as serine protease inhibitor (SERPIN)B1 have been demonstrated to hold protective functions against neutrophil protease-induced tissue damage in BPD [71].

In comparison to adult immune functions, term and preterm newborn infants show fewer peripheral blood neutrophil counts [72]. At 22–23 weeks of gestation, only 2% of all leukocytes in the peripheral blood are neutrophils, while these counts increase to 60% in term-born infants [55] and about 60–70% in adults [73].
Functionally, neonatal neutrophils show the deficiency to form neutrophil extracellular traps (NETs) [74] as well as a lower cell surface expression of L-selectin [72]. Following injury, endothelial cells express leucocyte adhesion molecules on their luminal side, particularly P- and E-selectins, together with several integrin members of the ICAM family, to allow adhesion of neutrophils through their respective selectin ligands and integrins, e.g., CD18 and CD11b [75]. Neonatal neutrophils, however, express lower levels of CD11b and subsequently display only attenuated abilities for adhesion as compared to adult cells. Also, reduced neutrophil CD18 and L-Selectin expression levels have even been described for their predictive value in BPD [76] while it has been reported that the ratio of blood neutrophil to lymphocyte has been increased 72 h after birth [12]. The latter points to an inflammatory stimulation in utero encompassing the lung. Nevertheless, reduced blood neutrophil levels have to be viewed in light of a potential imbalance of tissue accumulation and BM production [77]. The vulnerability of the newborn lung towards inflammatory injury is highlighted by findings in bronchoalveolar lavage fluid (BALF) demonstrating the combination of MV, hyperoxia, and inflammation to trigger the expression of acute-phase cytokines and chemokines in newborn infants [78] together with increased neutrophil apoptosis where intact neutrophils are phagocytosed by AMs before degranulation [79]. These findings might reflect a mechanism contributing to sustained inflammation and tissue damage. Neutrophil-related events as a therapeutic approach are still being explored.

The second wave of inflammation, induced by the neutrophil through releasing chemoattractants, involves the recruitment of other immune cells, specifically monocytes/macrophages.

Monocytes/macrophages and their response in BPD developing infants

Since the lung is the interface to the external environment and related immunological challenges [80], mononuclear phagocytic cells are dedicated to confronting these challenges. Therefore, in response to environmental insults, circulating monocytes migrate into the alveolar space and contribute to the process of alveolar injury and remodeling [81, 82]. Monocyte/macocyte-derived alveolar macrophages (Mo-AMs) recruitment to the lung is a characteristic process in BPD [83], even in light of a reduced number of monocytes in the neonatal peripheral tissue per se [84] and their lower adherence and transmigration capacity when facing the non-inflamed endothelium [84].

The process seems to mark chronification in BPD despite the potential to contribute to the resolution of inflammation in the first place. Like neutrophils, monocytes originate from the granulocyte monocyte progenitor (GMP) in the BM and play a key role in innate immune responses which are closely related to vascular homeostasis [85, 86] and contribute to processes such as phagocytosis and lung regeneration at the same time. These functions have in part been attributed to modulating alveolar stem cells [87, 88].

Current concepts relate to three human monocyte subsets: classical (CD14+CD16−), non-classical (CD14+CD16+), and intermediate (CD14+CD16+) monocytes [89]. Each subset holds unique functions represented by different surface markers [90]. The differing abilities regarding recruitment, cytokine production, and capability of endothelial activation [91] relate to the grouping introduced above. Whereas nonclassical/intermediate monocytes secrete higher levels of TNFα and demonstrate an increased capacity for endothelial transmigration, classical monocytes secrete high levels of IL-6, and assist neutrophil recruitment [91]. In mice—in relation to the human concept—main types of monocytes are identified according to three subsets including classical (Ly6C++ , CCR2++, CD43+), nonclassical (Ly6C+, CCR2+, CD43++, CX3CR1+), and intermediate (Ly6C++, Trem2++, CD43++) monocytes [92–95]. Here, Ly6C+ nonclassical monocytes continuously scan the endothelium for injury and infections [96] and are thereby involved in maintaining endothelial barrier integrity, regeneration, and repair [97–99].

Monocytes respond to chemokine signals with the adhesion to endothelial cells following a multistep adhesion cascade involving the interaction of leukocyte adhesion molecules for instance L-selectin, PSGL1, LFA1, MAC1, VLA4, and their respective receptors on endothelial cells from the selectin and immunoglobulin superfamily [85, 86, 100–102]. Adhesion dynamics and homeostatic extravasation is depending on CD31 and CD54 expression levels [84]. Monocytes from preterm infants, however, show a lower surface expression of the CD11b/CD18 and CD31 adhesion receptors, resulting in a reduced ability for extravasation and greater susceptibility to infections [84, 103]. Necessary for the subsequent differentiation of fetal monocytes into pre-AMs during embryonic development, the transforming growth factor (TGF)-β1 is simultaneously a key player in lung development. Its dual role next in inflammation and apoptosis [104, 105] and the dynamic regulation during alveolarization renders the prenatal regulation of TGF-β during in utero inflammation an interesting target [106, 107]. TGF-β1 is an important factor for AM maturation after birth as well as for the homeostasis of adult
AMs [108] and provides important signals for monocyte recruitment [109] and their activation. Whereas CD14+ monocytes stimulate the TGF-β1 pathway through the expression of the integrin αvβ8, this is not observed for CD16+ monocytes [110].

After exiting the circulation, blood-derived monocytes rapidly differentiate into highly phagocytic active macrophages which are innate immune cells that are abundant in tissues [111]. In many organs, including the lung, they are divided into tissue-resident macrophages (TRMs) and “monocyte-derived” macrophages (Mo-Ms) [38, 82, 111]. While the latter are continuously generated and replaced from the BM hematopoietic system, TRMs are derived during embryonic development from erythro-myeloid progenitors of the yolk sac (YS) and fetal liver monocytes [112, 113]. TRMs are abundant in lung alveoli and contribute to the formation of the alveolar niche in the first week of life [114]. TRMs can develop from fetal monocytes by gaining an established phenotype shortly after birth in response to instructive cytokines. Furthermore, they are able to self-maintain throughout life [115]. YS-derived macrophages and fetal monocytes can arise as identical alveolar macrophages, while mostly the fetal monocytes colonize the alveolar area [116]. Tissue-resident alveolar macrophages (TRM-AM) play a central role in lung development, tissue homeostasis, and immune responses. Their absence leads to infections and alveolar proteinosis due to loss of protein clearance [115]. Their contribution to the formation of the alveolar niche in the first weeks of life as well as to disease development is of current interest [112–115, 117, 118]. Although the exact contribution of the macrophage lung in the pathogenesis of BPD has not been elucidated yet, adequate early macrophage activation of macrophages is shown to be crucial to protecting infants lungs from the development of BPD [119].

Several studies have shown that Mo-AMs play an important role in endotoxin-induced, acute lung inflammation [52, 120–122]. However, as the maturation of the lung macrophages is a postnatal process, preterm and term newborns are rendered more susceptible to disease until a “catch up” is achieved if at all [123], further aggravated by the reduced number of lung TRM-AM [124]. Monocytes and Mo-AMs from preterm infants less than 30 weeks of gestation, even show impaired pro-inflammatory cytokine production, i.e., IL-8, IL-1β, IL-6, and TNFα [9, 125–127], together with a deficient pathogen response in comparison to adults, enhancing the infection and damage susceptibility further [128].

Both MV and oxygen exposure of the underdeveloped lung provokes oxidative stress [63, 129], in turn leading to increased expression of pro-inflammatory cytokines such as TNFα, IL-8, IL-1β, and IL-6 tracheobronchial aspirates [130–132]. These multiple-hit events are self-perpetuating when adding the crosstalk with the epithelial cells engaged in cytokine expression, NF-κB activity, and ROS production which results in monocyte recruitment and macrophage differentiation [133].

**Disease modeling of BPD by focusing on innate immune cells**

The role of neutrophils and monocytes in BPD onset and progression is studied using different methods and models, mainly relying on 2D cell cultures and measurement in clinical samples to complex animal models (Table 1). Several studies addressed the innate immune system in the lung compartment by the use of BAL, TA specimens, cord blood cells, and serum from preterm and term neonates in the first week of life [24, 45, 134–136]. Patient-derived samples are valuable pre-clinical tools for defining predictive biomarkers in disease development. However, isolating the untouched innate immune cells for in vitro studies can significantly affect their phenotype [137]. Several non-human species studies, which used mice, sheep, and baboons have been performed to study the BPD [13, 71, 124]. The experimental use of both prenatal and postnatal lung injury including MV and oxygen exposure in wild-type and transgenic animals attempts to investigate the cellular and molecular mechanisms of the development of disease in a preclinical setting [8, 13, 124, 138]. Differences between animal and human development of immune functions render these studies challenging. In addition, different in vitro models using primary cells or primary cell lines are added to gain insight into injury-relevant mechanisms of the innate immune cell [49, 139]. However, to the best of our knowledge, realistic in vitro models which mimic the physiological and pathophysiological of the lung with a focus on the migration of neutrophils and monocytes under static or dynamic conditions have not been employed in the field of BPD research thus far [139–141].

To provide an overview, we summarized relevant models for studying neutrophil and monocyte functions in the injured developing lung in chronological order in Table 1.

**Conclusions and outlook**

In summary, the immature lung undergoing injury is characterized by increased concentrations of pro-inflammatory cytokines as exemplified by measurements in TA obtained from very premature infants in the first days of life. While infections, oxygen exposure, and MV...
contribute to BPD development, the affected innate immune functions play a critical role in this complex disease of prematurity. During the past few years, significant efforts have been made to examine the role of inflammation-induced lung injury considering both prenatal and postnatal conditions while using human samples and animal models. Studies showed that a preterm neonate with a structurally and functionally immature lung, paired with an underdeveloped immune response exhibit an increased pro-inflammatory response when BPD develops. Therefore, targeting the inflammatory process is considered a therapeutic or preventive approach for BPD. Nonetheless, many conflicting results remain. Prematurity as such results in a smaller pool of neutrophils and monocyte/macrophages and a subsequently lower capacity to secrete cytokines and reach pathogen clearance. In BPD, however, elevated numbers of neutrophils and monocytes, and their inflammatory cytokines can be detected in the diseased lung. The differences in local and systemic concentrations may relate to mechanisms driving tissue accumulation despite reduced BM production rates. Targeting the number of peripheral blood immune cells has been suggested as a therapeutic strategy in BPD. Nevertheless, this approach neglects the developmental functions, the same innate immune cells, and their signaling molecules hold.

### Table 1

| Year | Model/specimen | Main findings on the role of neutrophils and monocytes in BPD | Ref |
|------|----------------|-----------------------------------------------------------|-----|
| 1984 | Human neonatal BAL | Neutrophil influx and imbalance between elastase and alpha 1-proteinase inhibitor contribute to BPD development. | [134] |
| 2001 | Human neonatal TA | MCP-1 and IL-8 increase describes BPD and is correlated to oxygen exposure and duration of MV. | [135] |
| 2003 | Fetal and neonatal lamb | Monocytes from preterm and term lambs differ from the adult cells regarding inflammation initiation and resolution. | [124] |
| 2004 | Human neonatal cells | Decreased CD18 expression on neutrophils and monocytes and CD62L on neutrophils are early predictors of BPD. | [76] |
| 2004 | Neonatal rat | The combination of hyperoxia exposure and neutrophil accumulation has a pivotal role in the development of BPD. | [67] |
| 2007 | Human placenta and cord blood | Neonatal monocytic IL-10 production is below the needed for inhibition of release of IL-8. Suggesting exogenous IL-10 as a BPD treatment strategy. | [136] |
| 2008 | Human neonatal blood | Low neutrophil counts in the systemic circulation might predict BPD severity. | [142] |
| 2009 | Neonatal sheep | Prenatal inflammation affects fetal immune responses including the maturation of monocytes to AMs. | [13] |
| 2011 | Neonatal mice | MV-O2 leads to an increased accumulation of neutrophils and monocytes/macrophages in the lung. | [143] |
| 2013 | Neonatal mice | Perinatal inflammation and postnatal hyperoxia mark the activation of the macrophages which can be enhanced by IL-1Ra. | [144] |
| 2015 | Neonatal mice | Increased TGFβ1 expression in leads to apoptosis and monocyte and macrophage infiltration. | [145] |
| 2016 | Neonatal mice | MV increases the infiltrating monocytes and cytokine expression in the lungs of TNFα−/− mice in comparison to the WT. | [138] |
| 2018 | Neonatal mice | Csfr1 expressing monocyte/macrophage lineage are critical mediators of arrested alveolarization. | [83] |
| 2019 | Human neonatal blood | The elevated neutrophil-to-lymphocyte ratio is an early predictor of BPD. | [12] |
| 2019 | Neonatal mice and human neonatal TA | The presence of neutrophil-derived pathogenic in BPD lung secretion promotes extracellular matrix destruction. | [66] |
| 2019 | Human neonatal TA | Association between early changes in monocyte-specific IL-1 cytokine and evolving BPD. | [24] |
| 2019 | Neonatal mice and human neonatal TA | Inhibition of miR199a-5p improves lung vascular leak and decreased BALF total cell counts including macrophages and neutrophil influx. | [146] |
| 2020 | Neonatal rat | Long-term hyperoxia exposure reduced the number of peripheral blood neutrophils in BPD. | [77] |
| 2020 | Human neonatal TA | Identify higher expression of inflammatory mediator genes on the first day of life as a predictive BPD signature. | [123] |
| 2021 | Neonatal mice | Csf1r expressing monocyte/macrophage lineage are critical mediators of arrested alveolarization. | [83] |
changed into an immune reaction while infection clearing and termination of inflammation are not reached. The subsequent release of damage signals initiates the detrimental cascade of alveolar and airway injury.

Future studies need to overcome current limitations that exist due to a variety of reasons. First of all—given the nature of the patient collective—only a limited number of preterm infants can be enrolled in the majority of studies. Secondly, volume restrictions of clinical samples obtained from preterm infants limit the experimental settings in addition to the non-physiological activation of primary cells during isolation and culture. Hence, reliable analysis techniques and the avoidance of solely targeted approaches need to be combined with optimized “preclinical” in vitro models to overcome the described challenges. The establishment of large datasets standardized or harmonized between centers and groups including single-cell analysis will help to provide valuable resources for studies to come regarding both developmental and injury functions of the innate immune system. Preclinical animal models—despite the differences in immune regulation processes and marker expression when comparing mice and men—should be combined to tackle context-related knowledge gaps putting in vitro findings into perspective concerning cellular crosstalk and spatial resolution.

In the future, our understanding of the role of the immune system in BPD will become increasingly important as more sophisticated therapeutic and diagnostic possibilities emerge that may allow targeted approaches to treat and monitor disease-relevant processes in a population tackling critical steps of organ development.

Abbreviations
MV: Mechanical ventilation; GA: Gestational age; BAL: Bronchoalveolar lavage; TA: Tracheal aspirate; bpd: Bronchopulmonary dysplasia; nCLD: Neonatal chronic lung disease; AMs: Alveolar macrophages; TRM: Tissue-resident macrophages; Mo-Ms: Monocyte-derived macrophages; Mo-AMs: Monocyte-derived alveolar macrophages; RDS: Respiratory distress syndrome; BLF: Bronchoalveolar lavage fluid; NETs: Neutrophil extracellular traps; TGF-β1: Transforming growth factor; G-CSF: Granulocyte colony-stimulating factor; ROS: Reactive oxygen species; MCP: Monocyte chemoattractant proteins; MMP: MMP-9: Metalloproteinases-9; YS: Yolk sac.

Acknowledgements
We strived to cover all the papers related to the topic of the present review paper. We, however, apologize for any missing references. In part, the schematic was created using the Motifolio biology toolkit.

Authors’ contributions
M. H. and A. H. conceptualized and wrote the first draft of the manuscript. M. H. designed the figure and table. M. H., C. S., T. S., and A. H. wrote and revised the final manuscript. The author(s) read and approved the final manuscript.

Funding
Open Access funding enabled and organized by Projekt DEAL. The present study work was supported by the German Center for Lung Research (DZL), German Ministry of Education and Health (BMBF) as well as the Research Training Group Targets in Toxicology (GRK2338) of the German Science and Research Organization (DFG). Additional support was provided by the Stiftung AtemWeg (LSS AIRR).

Availability of data and materials
Not applicable.

Declarations
Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Institute for Lung Health and Immunity and Comprehensive Pneumology Center with the CPC-M bioArchive, Helmholtz Center Munich, Member of the German Center for Lung Research (DZL), Munich, Germany. 2 German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany. 3 Department of Medicine I, University Hospital, Ludwig Maximilian University, Munich, Germany. 4 Center for Comprehensive Developmental Care (CDeGLMU) at the interdisciplinaty Social Pediatric Center, (iSPZ2), University Hospital Ludwig-Maximilian University, Munich, Germany.

Received: 12 April 2022 Accepted: 15 July 2022
Published online: 02 August 2022

References

1. Niedermaier S, Hilgendorff A (2015) Bronchopulmonary dysplasia - an overview about pathophysiologic concepts. Mol Cell Pediatr 2:2. https://doi.org/10.1186/s40348-015-0013-7
2. Glass HC, Costarino AT, Stayer SA et al (2015) Outcomes for extremely premature infants. Anesth Analg 120:1337–1351. https://doi.org/10.1213/ANE.0000000000000705
3. McGeachie MJ, Yates KP, Zhou X et al (2016) Patterns of growth and decline in lung function in persistent childhood asthma. N Engl J Med 374:1842–1852. https://doi.org/10.1056/NEJMoa1513737
4. Tong Y, Zhang S, Riddle S et al (2021) Intrauterine hypoxia and epigenetic programming in lung development and disease. Biomedicines 9:444. https://doi.org/10.3390/biomedicines9080444
5. Binwale MA, Ehrenkranz RA (2006) The role of nutrition in the prevention and management of bronchopulmonary dysplasia. Semin Perinatol 30:200–208. https://doi.org/10.1053/j.semperi.2006.05.007
6. Trembath A, Laughon MM (2012) Predictors of bronchopulmonary dysplasia. Clin Perinatol 39:585–601. https://doi.org/10.1016/j.clp.2012.06.014
7. Riyas PK, Vijayakumar KM, Kulkarni ML (2003) Neonatal mechanical ventilation. Indian J Pediatr 70:537–540. https://doi.org/10.1007/BF02723151
8. Mokes LM, Parai K, Hilgendorff A et al (2010) Prolonged mechanical ventilation with air induces apoptosis and causes failure of alveolar septation and angiogenesis in lungs of newborn mice. Am J Physiol Cell Mol Physiol 298:L23–L35. https://doi.org/10.1152/ajpcell.00251.2009
9. Jong E, Strunk T, Burgner D et al (2017) The phenotype and function of preterm infant monocytes: implications for susceptibility to infection. J Leukoc Biol 102:645–656. https://doi.org/10.1189/jlb.4ru0317-111r
10. Driscoll NE, Carter JM, Hassinen DG, Howard B (1997) Cytokines and particle-induced inflammatory cell recruitment. Environ Health Perspect 105:1159–1164. https://doi.org/10.1289/ehp.9710551159
11. Gronpeck P, Götze-Speer B, Oppermann M et al (1994) Association of pulmonary inflammation and increased microvascular permeability during the development of bronchopulmonary dysplasia: a sequential analysis
of inflammatory mediators in respiratory fluids of high-risk preterm neonates. Pediatrics 93:712–718.

12. Sun Y, Chen C, Zhang X et al (2019) High neutrophil-to-lymphocyte ratio is an early predictor of bronchopulmonary dysplasia. Front Pediatr 7:1–9. https://doi.org/10.3389/fped.2019.00464.

13. Kramer BW, Kallapur S, Newnham J, Jobe AH (2009) Prenatal inflammation and lung development. Semin Fetal Neonat Med 14:2–7. https://doi.org/10.1016/j.siny.2008.08.011.

14. Balany J, Bhandari V (2015) Understanding the impact of infection, inflammation, and their persistence in the pathogenesis of bronchopulmonary dysplasia. Front Med 2:1–10. https://doi.org/10.3389/fmed.2015.00090.

15. Wright RJ, Visness CM, Calatroni A et al (2010) Prenatal maternal stress and cord blood innate and adaptive cytokine responses in an inner-city cohort. Am J Respir Crit Care Med 182:25–33. https://doi.org/10.1164/rccm.200906-0637OK.

16. Humberg A, Fortmann J, Siller B et al (2020) Preterm birth and sustained inflammation: consequences for the neonate. Semin Immunopathol 42:451–468. https://doi.org/10.1007/s00281-020-00803-2.

17. Agrawal V, Hirsch E (2012) Intrauterine infection and preterm labor. Semin Fetal Neonat Med 17:12–19. https://doi.org/10.1016/j.siny.2011.09.001.

18. Bash A, Surendran N, Pichichero M (2014) Immune responses in neonates. Expert Rev Clin Immunol 10:1171–1184. https://doi.org/10.1586/147666X.2014.942288.

19. Palmeira P, Quinellio C, Silveira-Less A et al (2012) IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol 2012:1–13. https://doi.org/10.1155/2012/856466.

20. Speer CP (2006) Pulmonary inflammation and bronchocellulmonary dysplasia. J Perinatol 26:557–562. https://doi.org/10.1016/j.jpain.2006.03.001.

21. Speer CP (2006) Inflammation and bronchocellulmonary dysplasia: a continuing story. Semin Fetal Neonat Med 11:354–362. https://doi.org/10.1016/j.siny.2006.06.008.

22. Goetz MI, Kremer S, Behnke J et al (2021) MSC based therapies to prevent or treat BPD—a narrative review on advances and ongoing challenges. Int J Mol Sci 22:1138. https://doi.org/10.3390/ijms22051138.

23. Heydarian M, Schweinlin M, Schwarz T et al (2021) Triple co-culture and chemokine system in innate immunity. J Invest Dermatol 2017:1–11. https://doi.org/10.1155/2017/3908061.

24. Eldredge LC, Creasy RS, Presnell S et al (2019) Infants with evolving bronchopulmonary dysplasia demonstrate monocyte-specific expression of IL-1 in tracheal aspirates. Am J Physiol Cell Mol Physiol 317:L49–L56. https://doi.org/10.1152/ajpcell.0012019.

25. Levy O (2007) Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat Rev Immunol 7:379–390. https://doi.org/10.1038/nri2075.

26. Yu JC, Khodadadi H, Malik A et al (2018) Innate immunity of neonates and infants. Front Immunol 9. https://doi.org/10.3389/fimmu.2018.01759.

27. Newburg DS, Walker WA (2007) Protection of the neonate by the innate immune system of developing gut and of human milk. Pediatr Res 61:2–8. https://doi.org/10.1203/pdr.0000000000002718.

28. MacGillivray DM, Kollmann TR (2014) The role of environmental factors in the pathogenesis of bronchopulmonary dysplasia. Pediatr Pulmonol 50:451–468. https://doi.org/10.1002/ppul.23414.

29. Sokol CL, Luster AD (2014) From monocytes to M1/M2 macrophages: phenotypical vs. functional differentiation. Front Immunol 5:1–22. https://doi.org/10.3389/fimmu.2014.00514.

30. Honda A, Hoekema MA, Sakai M et al (2022) The lung microenvironment instructs gene transcription in neonatal and adult macrophages. J Immunol 26:2101192. https://doi.org/10.4049/jimmunol.26:2101192.

31. Ambalavanan N, Carlo WA, D’Ango CT et al (2009) Cytokines associated with bronchopulmonary dysplasia or death in extremely low birth weight infants. Pediatrics 123:1132–1141. https://doi.org/10.1542/peds.2008-0526.

32. Baier RJ, Majid A, Parupia H et al (2004) CC chemokine concentrations increase in respiratory distress syndrome and correlate with development of bronchopulmonary dysplasia. Pediatr Pulmonol 37:157–148. https://doi.org/10.1002/ppul.10417.

33. Bose CL, Dammann CEI, Laughon MM (2008) Bronchopulmonary dysplasia and inflammatory biomarkers in the premature neonate. Arch Dis Child - Fetal Neonatal Ed 93:F455–F461. https://doi.org/10.1136/adc.2007.121327.

34. Wagenaar GTM, ter Horst SA, van Gastelen MA et al (2004) Gene expression profile and histopathology of experimental bronchopulmonary dysplasia induced by prolonged oxidative stress. Free Radic Biol Med 36:782–801. https://doi.org/10.1016/j.freeradbiomed.2003.12.007.

35. Köksal N, Kayık B, Çetinikaya M et al (2012) Value of serum and bronchoalveolar fluid lavage pro- and anti-inflammatory cytokine levels for predicting bronchopulmonary dysplasia in premature infants. Eur Cytokine Netw 23:29–35. https://doi.org/10.1684/ecn.2012.0304.

36. Baier RJ, Loggins J, Kruger TE (2003) Interleukin-4 and 13 concentrations in infants at risk to develop Bronchopulmonary Dysplasia. BMC Pediatr 3. https://doi.org/10.1186/1471-2431-3-8.

37. Cai J, Hu S, Liu Z et al (2022) Dynamic changes of NCR.− in infants at risk to develop Bronchopulmonary Dysplasia. Pediatr Pulmonol 50:451–468. https://doi.org/10.1002/ppul.23414.

38. Kuwabara T, Ishikawa F, Kondo M, Kakiuchi T (2017) The role of IL-17 and related cytokines in inflammatory autoimmune diseases. Mediators Inflamm 2017:1–11. https://doi.org/10.1155/2017/3908061.

39. Schibler KR, Liechty KW, White WL, Christensen RD (1993) Production of granulocyte colony-stimulating factor in vitro by monocytes from preterm and term neonates. Blood 82:2478–2484. https://doi.org/10.1182/blood.V82.8.2478.2478.

40. Wright CJ, Kirpalani H (2011) Targeting inflammation to prevent bronchopulmonary dysplasia. N Engl J Med 365:798–807. https://doi.org/10.1056/nejmp1100411.

41. Savani RC (2018) Modulators of inflammation in bronchopulmonary dysplasia. Semin Perinatol 42:459–470. https://doi.org/10.1053/j.semperi.2018.09.009.

42. Beck-Schimmer B, Schwendener R, Pasch T et al (2005) Alveolar macrophages regulate neutrophil recruitment in endotoxin-induced lung injury. Respir Res 6:61. https://doi.org/10.1186/1465-9921-6-61.

43. Phillipson M, Kubis P (2011) The neutrophil in vascular inflammation. Nat Med 17:1381–1390. https://doi.org/10.1038/nm.2514.

44. Aggarwal NR, King LS, D’Alessio FR (2014) Diverse macrophage populations mediate acute lung inflammation and resolution. Am J Respir Cell Mol Biol 50:315–326. https://doi.org/10.1165/rcmb.2013-0305OC.
98. Glod J, Kobiler D, Noel M et al (2006) Monocytes form a vascular barrier and participate in vessel repair after brain injury. Blood 107:940–946. https://doi.org/10.1182/blood-2004-11-4403

99. Hernandez GE, Iruela-Anspe ML (2020) The many flavors of monocyte/macrophage—endothelial cell interactions. Curr Opin Hematol 27:181–189. https://doi.org/10.1097/MOH.0000000000000573

100. van Gils JM, Zwagginga JJ, Hordijk PL (2009) Molecular and functional interactions among monocytes, platelets, and endothelial cells and their relevance for cardiovascular diseases. J Leukoc Biol 85:195–204. https://doi.org/10.1189/jlb.0709404

101. Hakker B, Kuijpers T, Leeuwenberg J et al (1991) Neutrophil and monocyte adherence to and migration across monolayers of cytokine-activated endothelial cells: the contribution of CD18, ELAM-1, and VLA-4. Blood 78:2721–2726. https://doi.org/10.1182/blood.V78.27.2721

102. Gordon S (1995) The macrophage. BioEssays 17:977–986. https://doi.org/10.1002/bies.95017111

103. Kaufman D, Kilpatrick L, Hudson RG et al (1999) Decreased superoxide production by monocyte/macrophages of preterm newborns and respiratory disease. J Child Sci 07:e110–e119. https://doi.org/10.1055/s-00037-1605579

104. Jonsson B, Tullus K, Brauner A et al (2016) Early increase of TNFalpha and IL-6 in tracheobronchial aspirate fluid indicator of subsequent chronic lung disease in preterm infants. Arch Dis Child Fetal Neonatal Ed 77:F198–F201. https://doi.org/10.1136/fn.77.3.F198

105. Kramer BW, Jobe AH, Ikegami M (2003) Monocyte function in preterm, term, and adult sheep. Pediat Dis 85:52–57. https://doi.org/10.1378/chest.125.2.754

106. Kelly A, Gunaltay S, McEntee CP et al (2018) Human monocytes and macrophages regulate immune tolerance via integrin αvβ8-mediated TGF-β activation. Exp Hematol 43:564. https://doi.org/10.1016/j.exphem.2015.06.130

107. Kramer BW, Jobe AH, Ikegami M (2003) Monocyte function in preterm, term, and adult sheep. Pediat Dis 85:52–57. https://doi.org/10.1378/chest.125.2.754

108. Alejandre-Alcázar MA, Michiels-Corsten M, Vicencio AG et al (2008) Cytokine/macrophage–endothelial cell interactions. Curr Opin Hematol 4. https://doi.org/10.1186/s40348-017-0076-8

109. Yu X, Buttgereit A, Lelios I et al (2017) The cytokine TGF-β promotes the fates of resident and recruited macrophages during resolution of acute lung injury. Am J Respir Crit Care Med 184:547–560. https://doi.org/10.1164/rccm.201011-1891OC

110. Wahl SM, Hunt DA, Wakefield LM et al (1987) Transforming growth factor type beta induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci USA 84:5788–5792. https://doi.org/10.1073/pnas.84.16.5788

111. Tullus K, Noack GW, Burman LG et al (2020) Impaired functional capacity of polarized neonatal macrophages. Sci Rep 10:1–12. https://doi.org/10.1038/s41598-019-56928-y

112. Yang J, Zhang L, Yu C et al (2014) Monocyte and macrophage differentiation: circulation inflammatory monocyte as biomarker for inflammatory diseases. Biomark Res 2:1–9. https://doi.org/10.1186/2050-7717-2-1

113. Janssen WJ, Barthel L, Muldrow A et al (2011) Fas determines differential fates of resident and recruited macrophages during resolution of acute lung injury. Am J Respir Crit Care Med 184:547–560. https://doi.org/10.1164/rccm.201011-1891OC

114. Tullus K, Noack GW, Burman LG et al (2020) Impaired functional capacity of polarized neonatal macrophages. Sci Rep 10:1–12. https://doi.org/10.1038/s41598-019-56928-y

115. Hoeffel G, Chen J, Lavin Y et al (2015) C-Myb phosphorylation is dynamically regulated during the alveolarization of rodent and human lungs. Dev Dyn 237:259–269. https://doi.org/10.1002/dvdy.24103

116. Perdiguero EG, Klapproth K, Schulz C et al (2015) Tissue-resident macrophages are shaped by the local microenvironment. Cell 161:1312–1326. https://doi.org/10.1016/j.cell.2014.11.018

117. Evren E, Ringqvist E, Doisne J-M et al (2022) CD116+ fetal precursors migrate to the perinatal lung and give rise to human alveolar macrophages. J Exp Med 219. https://doi.org/10.1186/s41598-017-0076-8

118. Yang J, Zhang L, Yu C et al (2014) Monocyte and macrophage differentiation: circulation inflammatory monocyte as biomarker for inflammatory diseases. Biomark Res 2:1–9. https://doi.org/10.1186/2050-7717-2-1

119. Milan A, Pirante E, Nardo D et al (2017) Early macrophage activation in preterm newborns and respiratory disease. J Child Sci 07:e110–e119. https://doi.org/10.1055/s-00037-1605579

120. Atochina-Vasserman EN, Bates SR, Zhang P et al (2011) Early alveolar epithelial dysfunction promotes lung inflammation in a mouse model of Hermansky-Pudlak Syndrome. Am J Respir Crit Care Med 184:449–458. https://doi.org/10.1164/rccm.201101-1182OC

121. Jonsson B, Tullus K, Brauner A et al (2016) Early increase of TNFα and IL-6 in tracheobronchial aspirate fluid indicator of subsequent chronic lung disease in preterm infants. Arch Dis Child Fetal Neonatal Ed 77:F198–F201. https://doi.org/10.1136/fn.77.3.F198

122. Li L, Chen J, Xiong G et al (2016) Increased ROS production in non-polarized mammary epithelial cells induces monocyte infiltration in 3D culture. J Cell Sci 130:190–202. https://doi.org/10.1242/jcs.186031

123. Ogden BE, Murphy SA, Saunders GC et al (1984) Neonatal lung neutrophils and elastase/proteinase inhibitor imbalance. Am Rev Respir Dis 130:817–821. https://doi.org/10.1186/1349-1843.130.5.817

124. Baier JR, Loggins J, Kruger TE (2001) Monocyte chemoattractant protein-1 and interleukin-8 are increased in bronchopulmonary dysplasia. J Invest Med 49:362–369. https://doi.org/10.2310/AMJIM.0:00010432

125. Nielsen MC, Andersen MN, Møller HJ (2020) Monocyte isolation techniques significantly impact the phenotype of both isolated monocytes and derived macrophages in vitro. Immunology 159:63–74. https://doi.org/10.1111/imn.13125

126. Ehrhardt H, Pritzke T, Oak P et al (2016) Absence of TNFα enhances inflammatory response in the newborn lung undergoing mechanical...
ventilation. Am J Physiol - Lung Cell Mol Physiol 310:L909–L918. https://doi.org/10.1152/ajplung.00367.2015

139. Oak P, Pritzke T, Thiel I et al (2017) Attenuated PDGF-signalling drives alveolar and microvascular defects in neonatal chronic lung disease. EMBO Mol Med 9:1504–1520. https://doi.org/10.15252/emmm.201607308

140. Prenster M, Kurz ARM, Chung K-J et al (2017) Attenuated PDGF signaling drives alveolar and microvascular defects in neonatal chronic lung disease. EMBO Mol Med 9:1504–1520. https://doi.org/10.15252/emmm.201607308

141. Doryab A, Tas S, Taskin MB et al (2019) Evolution of bioengineered lung models: recent advances and challenges in tissue mimicry for studying the role of mechanical forces in cell biology. Adv Funct Mater 29:1903114. https://doi.org/10.1002/adfm.201903114

142. Pruenster M, Sadek-Badawi M, Carlton DP (2008) Association of BPD and IVH with early neutrophil and white counts in VLBW neonates with gestational age <32 weeks. J Perinatol 28:604–610. https://doi.org/10.1038/jp.2008.65

143. Hilgendorff A, Parai K, Ertsey R et al (2011) Inhibiting lung elastase activity enables lung growth in mechanically ventilated newborn mice. Am J Respir Crit Care Med 184:537–546. https://doi.org/10.1164/rcrm.201012-2010OC

144. Nold MF, Mangan NE, Rudloff I et al (2013) Interleukin-1 receptor antagonist prevents murine bronchopulmonary dysplasia induced by perinatal inflammation and hyperoxia. Proc Natl Acad Sci 110:14384–14389. https://doi.org/10.1073/pnas.1306859110

145. Sureshbabu A, Syed MA, Boddupalli CS et al (2015) Conditional overexpression of TGFβ1 promotes pulmonary inflammation, apoptosis and mortality via TGFBR2 in the developing mouse lung. Respir Res 16:4. https://doi.org/10.1186/s12931-014-0162-6

146. Alam MA, Betal SGN, Aghai ZH, Bhandari V (2019) Hyperoxia causes miR190a-5p-mediated injury in the developing lung. Pediatr Res 86:579–588. https://doi.org/10.1038/s41390-019-0524-3

147. Shrestha D, Ye GX, Stabley D et al (2021) Pulmonary immune cell transcriptome changes in double-hit model of BPD induced by chorioamnionitis and postnatal hyperoxia. Pediatr Res. https://doi.org/10.1038/s41390-020-01319-z

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.